======= KMT2E ======= == Gene Information == * **Official Symbol**: KMT2E * **Official Name**: lysine methyltransferase 2E * **Aliases and Previous Symbols**: N/A * **Entrez ID**: [[https://www.ncbi.nlm.nih.gov/gene/?term=55904|55904]] * **UniProt**: [[https://www.uniprot.org/uniprot/Q8IZD2|Q8IZD2]] * **Interactions**: [[https://thebiogrid.org/search.php?search=KMT2E&organism=9606|BioGRID]] * **PubMed articles**: [[https://www.ncbi.nlm.nih.gov/pubmed/?term=gene%20KMT2E|Open PubMed]] * **OMIM**: [[https://omim.org/entry/608444|Open OMIM]] == Function Summary == * **Entrez Summary**: This gene is a member of the myeloid/lymphoid or mixed-lineage leukemia (MLL) family and encodes a protein with an N-terminal PHD zinc finger and a central SET domain. Overexpression of the protein inhibits cell cycle progression. Alternate transcriptional splice variants have been characterized. [provided by RefSeq, Jul 2008]. * **UniProt Summary**: N/A |SET| |PHD| |positive regulation of histone H3-K4 trimethylation| |regulation of histone H3-K4 trimethylation| |positive regulation of histone H3-K4 methylation| |histone-lysine N-methyltransferase activity| |transcriptionally active chromatin| |regulation of histone H3-K4 methylation| |positive regulation of G1/S transition of mitotic cell cycle| |positive regulation of histone methylation| |positive regulation of cell cycle G1/S phase transition| |DNA alkylation| |DNA methylation| |regulation of megakaryocyte differentiation| |methylated histone binding| |regulation of histone methylation| |DNA methylation or demethylation| |histone lysine methylation| |positive regulation of mitotic cell cycle phase transition| |erythrocyte differentiation| |peptidyl-lysine methylation| |DNA modification| |erythrocyte homeostasis| |positive regulation of histone modification| |histone methylation| |positive regulation of cell cycle phase transition| |positive regulation of chromatin organization| |myeloid cell homeostasis| |chromatin| |protein methylation| |protein alkylation| |regulation of histone modification| |cell cycle arrest| |regulation of G1/S transition of mitotic cell cycle| |positive regulation of mitotic cell cycle| |microtubule organizing center| |regulation of cell cycle G1/S phase transition| |positive regulation of chromosome organization| |regulation of chromatin organization| |homeostasis of number of cells| |myeloid cell differentiation| |regulation of myeloid cell differentiation| |macromolecule methylation| |positive regulation of cell cycle process| |methylation| |peptidyl-lysine modification| |enzyme binding| |regulation of chromosome organization| |histone modification| |covalent chromatin modification| |positive regulation of cell cycle| |nuclear speck| |regulation of mitotic cell cycle phase transition| |regulation of cell cycle phase transition| |regulation of hemopoiesis| |neutrophil mediated immunity| |neutrophil activation| |granulocyte activation| |myeloid leukocyte mediated immunity| |hemopoiesis| |negative regulation of cell cycle| |myeloid leukocyte activation| |protein-containing complex| |hematopoietic or lymphoid organ development| |positive regulation of organelle organization| |regulation of mitotic cell cycle| |immune system development| |chromatin organization| |DNA metabolic process| |regulation of cell cycle process| |leukocyte mediated immunity| |peptidyl-amino acid modification| |leukocyte activation| |cell cycle process| |chromosome organization| |cell activation| |immune effector process| |regulation of cell cycle| |positive regulation of cellular component organization| |positive regulation of protein modification process| |regulation of organelle organization| |cell cycle| |positive regulation of transcription, DNA-templated| |positive regulation of cellular protein metabolic process| |positive regulation of nucleic acid-templated transcription| |positive regulation of RNA biosynthetic process| |homeostatic process| |regulation of immune system process| |positive regulation of protein metabolic process| |positive regulation of RNA metabolic process| |regulation of cell differentiation| |regulation of protein modification process| |positive regulation of nucleobase-containing compound metabolic process| |positive regulation of macromolecule biosynthetic process| |positive regulation of cellular biosynthetic process| |positive regulation of gene expression| |positive regulation of biosynthetic process| \\ === CRISPR Data === ^Screen^Score^ |[[:results:exp290|LLY-283 2.6μM R06 exp290]]|-2.88| |[[:results:exp499|LY2090314 0.003μM R08 exp499]]|-2.48| |[[:results:exp539|42°C R08 exp539]]|-2.3| |[[:results:exp299|Talazoparib 0.006μM R06 exp299]]|-1.96| |[[:results:exp500|LY2090314 0.003μM R08 exp500 no dilution day6]]|-1.94| |[[:results:exp175|3-Bromopyruvate 7μM R04 exp175]]|-1.87| |[[:results:exp2|5-Fluorouracil 20μM R00 exp2]]|-1.73| |[[:results:exp501|Methotrexate 0.01μM R08 exp501]]|-1.71| |[[:results:exp264|Arsenate 40μM R06 exp264]]|-1.71| |[[:results:exp256|HMS-I1 10μM R06 exp256]]|-1.7| |[[:results:exp321|ABT-702 5μM plus Deferoxamine 11μM R07 exp321]]|1.75| |[[:results:exp461|BS-181 20μM R08 exp461]]|1.75| |[[:results:exp145|PNU96415E 10μM R03 exp145]]|1.76| |[[:results:exp468|CB-5083 0.4μM R08 exp468]]|1.8| |[[:results:exp497|Lead acetate 2000μM R08 exp497]]|1.83| |[[:results:exp399|Salubrinal 20μM R07 exp399]]|1.91| |[[:results:exp71|KU-0063794 3.8μM R02 exp71]]|1.94| |[[:results:exp349|Cytochalasin-B 5μM R07 exp349]]|2.09| |[[:results:exp417|Tubastatin-A 2.5μM R07 exp417]]|2.13| |[[:results:exp29|Rapamycin 1μM R00 exp29]]|3.59| ^Gene^Correlation^ |[[:human genes:a:ankrd11|ANKRD11]]|0.495| Global Fraction of Cell Lines Where Essential: 0/726 ^Tissue^Fraction Of Cell Lines Where Essential^ |1290807.0|0/1| |909776.0|0/1| |bile duct|0/28| |blood|0/28| |bone|0/25| |breast|0/33| |central nervous system|0/56| |cervix|0/4| |colorectal|0/17| |esophagus|0/13| |fibroblast|0/1| |gastric|0/15| |kidney|0/21| |liver|0/20| |lung|0/75| |lymphocyte|0/14| |ovary|0/26| |pancreas|0/24| |peripheral nervous system|0/16| |plasma cell|0/15| |prostate|0/1| |skin|0/24| |soft tissue|0/7| |thyroid|0/2| |upper aerodigestive|0/22| |urinary tract|0/29| |uterus|0/5| == Essentiality in NALM6 == * **Essentiality Rank**: 7982 * **Expression level (log2 read counts)**: 7.51 {{:chemogenomics:nalm6 dist.png?nolink |}}